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A B S T R A C T
Cytochrome P450 1A1 (CYP1A1) is an enzyme participating in the bioactivation of various endogenous and environ-
mental reactive compounds that can bind to DNA and thus induce cancerogenesis. Gene encoding the enzyme is ex-
pressed in the prostate tissue and is polymorphic. CYP1A1*2A gene polymorphism is associated with elevated enzyme ac-
tivity and/or inducibility which can lead to accumulation of genotoxic compounds and consequently to cancerogenesis.
We examined the association of this polymorphism with prostate cancer (PCa) risk and aggressiveness. The case-control
study consisted of 120 PCa patients and 120 benign prostatic hyperplasia (BPH) controls, in Croatian population. Re-
garding aggressiveness, PCa patients were grouped according to the Gleason score (GS), tumor stage (T) and existence of
distant metastasis (M). The polymorphism was analyzed using real-time polymerase chain reaction (PCR). We did not
observe association of mutated allele with PCa risk, neither with PCa aggressiveness. Furthermore, frequency of poly-
morphic genotype was slightly higher in BPH group (16.6% vs. 14.2%, respectively) and also in less aggressive form of
PCa (20.4% vs. 9.6% for GS<7; 15.6% vs. 9.1% for T<3; 16.7% vs. 10.0% for no distant metastasis). Comparing our find-
ings with other published results, we can assume that the ethnicity influence the genotype distribution and thus may af-
fect the etiology of PCa, even possibly in the way to cause an opposite effect among different ethnic groups. Given the
small number of participants, results should be validated on the larger sample size.
Key words: CYPA1A1, single nucleotide polymorphism, prostate cancer, Croatia, polycyclic aromatic hydrocarbons,
smoking, DNA adducts, frequency, Gleason score, metastasis
Introduction
Prostate cancer is a major health problem in devel-
oped countries1,2 and the second cause of death among
cancers in men. In Croatians is the second most common
cancer in male population and shows increased inci-
dence3. Although the etiology of prostate cancer is un-
known, there are evidence that environmental factors
such as diet and lifestyle, chronic inflammation, and ge-
netic factors are important in the risk of development
and progression of the disease4,5. This is partly confirmed
by the large differences in the incidence among different
ethnic groups6, up to 50-fold7. Testing of gene polymor-
phisms therefore seems to be important area of investi-
gation.
The cytochrome P450 1A1 gene (CYP1A1) is located
on chromosome 15q22. It encodes phase I metabolism
enzyme with aryl hydrocarbon hydroxylase activity8. This
enzyme is involved in bioactivation of various environ-
mental carcinogen compounds like polycyclic aromatic
hydrocarbons (PAH) and polyaromatic amines. Besides,
it participates in oxidative metabolism of estrogens by
forming 2-hydroxy catechol estrogens (2-OHCE)8. Gen-
erated genotoxic products can bind to DNA, forming
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DNA-adducts and damaging the cell9. The CYP1A1 en-
zyme is expressed in prostate tissue4 and is highly induc-
ible by exposure to PAHs and other substances that bind
to aryl hydrocarbon (Ah) receptors10.
Several polymorphic variants within CYP1A1 have
been reported11. The CYP1A1*2A (rs4646903) occurs
due to T3801C substitution in the 3’ flanking region,
forming an Msp1 restriction site of the CYP1A1 gene
(CYP1A1m1)12. The polymorphic variant is associated
with elevated enzyme activity and/or inducibility8,12,
which can lead to accumulating of toxic, reactive inter-
mediaries. The incidence of the mutated allele is about
10% in Caucasians13 and shows marked interethnic vari-
ability. Previous studies showed a positive association of
CYP1A1*2A polymorphism with risk of lung14, cervix15,
bladder16 and gastric cancer17. Regarding association with
prostate cancer (PCa), results are controversial12.
In this study we determined frequencies of CYP1A1*
2A polymorphism in patients with PCa and benign pros-
tate hyperplasia (BPH) in Croatian population and esti-
mated the role of allele variants in development and ag-
gressiveness of PCa by themselves and in combination
with smoking.
Materials and Methods
Characterization of the sample
This case-control study comprises on 240 men who
were examined at the Department of Urology, University
Hospital Centre Osijek in 2008–2010. Subjects were di-
vided into two groups: 120 PCa patients and 120 patients
with BPH who represented controls. Groups were age
matched. Participants were subjected to digital rectal ex-
amination (DRE) and blood sampling for prostate spe-
cific antigen (PSA) testing. Subjects who had normal
DRE and PSA<4 ng/ml, or those with some other site of
cancer were excluded from the study. Those with ele-
vated PSA value and/or abnormal DRE, were subjected
to transrectal ultrasound (TRUS) – guided needle biopsy.
Diagnosis was confirmed by histopathological finding.
PCa patients were stratified according to the Gleason
score (GS), tumor stage (T) and existence of distant me-
tastasis (M). According to the GS, patients were grouped
as less aggressive form of cancer with GS<7 and highly
aggressive form with GS³7. According to the T, they were
divided into T<3 and T³3. Patients who were suspected
for the existence of distant metastasis underwent scin-
tigraphy and computed tomography (CT) and then were
classified as those who have distant metastasis (M1) and
those without them (M0). 2 of 120 patients did not have
data on the GS, T and M, and hence were excluded from
the testing of aggressiveness.
Patients fulfilled the questionnaire about clinical cha-
racteristics and gave signed informed consent of partici-
pation according to the guidelines by the Helsinki Decla-
ration. The study is approved by Ethic Committee of the
University Hospital Centre Osijek and by the Ministry of
Science, Education and Sports of the Republic of Croatia.
DNA isolation and genotyping
Genomic DNA was isolated from peripheral blood
lymphocytes using High Pure PCR Template Prepara-
tion Kit (Roche Diagnostics, Mannheim, Germany). De-
tection of CYP1A1 T3801C polymorphism was perfor-
med by real-time PCR and melting curve analysis on a
LightCycler 1.5 (Roche, Mannheim, Germany). The PCR
primers (5’-CCTGAACCCCATTCTGTGTTG-3’, 5’-AAA
AAAAAAAAAAAAAAAAAGCTGTG-3’) were synthesi-
zed by Invitrogen (Paisley, UK) and hybridization probes
(5’-CACCTCCCIGGCTCACACGATT-FL-3’, 5’-LCRed640-
CCACCTCAGCCTCTGAGTAGTTGGGG-P-3’) by TIB
MOLBIOL (Berlin, Germany) according to Harth et al.18.
PCR was performed in a total volume of 10 mL with
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TABLE 1
CHARACTERISTICS OF THE STUDY GROUPS
Characteristics
Cases Controls
N (%) N (%)
Sample size 120 120
Age (mean years±SD) 67.52±7.76 67.57±6.65
PSA (ng/mL)
Median (range) 12.35 (2.1–3346.0) 6.81 (0.57–28.0)
<4 7 (5.8) 15 (12.5)
4.1–10.0 39 (32.5) 76 (63.3)
10.1–20.0 30 (25.0) 26 (21.7)
>20.0 43 (35.8) 3 (2.5)
Family history of CaP
Negative 110 (91.7) 113 (94.2)
Positive 10 (8.3) 7 (5.8)
Smoking status
Non–smokers 94 (78.3) 99 (82.5)
Smokers 26 (21.7) 21 (17.5)
BMI (kg/m2)
<25 27 (22.9) 34 (29.1)
25–30 57 (48.3) 66 (56.4)
>30 34 (28.8) 17 (14.5)
TRUS (X±SD) 50.967±28.094 76.925±42.922
GS
<7 54 (45.8) –
³7 64 (54.2) –
Distant metastasis
M0 78 (66.1) –
M1 40 (33.9) –
Tumor stage
T<3 96 (81.4) –
T³3 22 (18.6) –
PSA – prostate specific antigen, BMI – body mass index, TRUS –
transrectal ultrasound, GS – Gleason score
30–60 ng of genomic DNA, 0.75 mM primers each, 0.3 mM
probes each, 4.0 mM MgCl2 and 1 x LC DNA Master Hy-
bridization Probes Mix (Roche, Mannheim, Germany).
The reaction mixtures were subjected to initial 2 min de-
naturation step at 94 °C followed by 52 cycles of denatur-
ation (94 °C / 3 s), annealing (58 °C / 20 s) and extension
(72 °C / 35 s). After amplification melting curve analysis
was performed (95 °C / 2 min / 20 °C / s, 48 °C / 1 min / 2 °C
/ s, 40 °C / 2 min / 2 °C / s, 80 °C / 0 s / 0.1 °C / s). The fluo-
rescence signal plotted against temperature gave peaks
at 61 °C and 68.5 °C for the allele T and C, respectively.
Statistical analysis
Fisher exact test was used for genotype and allele
comparison between groups. Odds ratio (OR) with 95%
confidence intervals (CI) were used for calculating the
strength of association of genotypes with cancer risk and
aggressiveness. Groups were tested for Hardy-Weinberg
equilibrium. To test the differences in body mass index
(BMI), PSA level and prostate volume values, t-test and
Mann-Whitney Rank Sum Test were used according to
the distribution. p<0.05 was considered statistically sig-
nificant. Statistical analysis were performed using Med-
Calc for Windows, version 12.4.0.0 (MedCalc Software,
Mariakerke, Belgium).
Results
In Table 1 are presented relevant demographic and
clinical data on CaP patients and BPH controls. Family
history of PCa and smoking status were similar between
groups, while PSA and TRUS values differed signifi-
cantly (p<0.001) as expected.
CYP1A1 genotype and allele frequencies did not differ
significantly between PCa patients and BPH controls.
Genotype frequencies for cases and controls were all in
Hardy-Weinberg equilibrium. No association between
PCa incidence and CYP1A1 polymorphism was found
(Table 2). The same table contains genotypes and alleles
distributions according to the smoking status, and ap-
propriate OR for PCa risk among smokers. We did not
observe any positive association by analyzing polymor-
phism and smoking together.
The results of testing association between mutated al-
lele and tumor parameters of aggressiveness are pre-
sented in Table 3. Obtained results showed lack of associ-
ation with GS, T and M status.
Discussion and Conclusion
In this study we analyzed prevalence of CYP1A1*2A
polymorphism in 120 PCa patients and 120 BPH controls
of Croatian population and assessed association of mu-
tated allele with PCa risk and aggressiveness. Besides,
we tested does smokers carriers of C allele have a higher
risk of PCa development.
Based on epidemiological studies it was confirmed
that environmental factors such as precarcinogens from
cigarette smoke and diet may be responsible for develop-
ment of numerous cancers. There are also numerous
studies concerning link between smoking and intake of
charbroiled meat with the incidence of PCa8. Experi-
ments have shown that potentially toxic compounds
which derive from such sources can be activated by
CYP1A1 into the compounds which are capable of bind-
ing to DNA. CYP1A1 is mainly expressed in extra hepatic
tissue including prostate, with high catalytic specificity
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TABLE 2




N (%) N (%)
TT 103 (85.5) 100 (83.3) 1.0 –
TC 17 (14.2) 20 (16.6) 0.83 (0.41–1.67) 0.592
CC 0 0 – –
T allele 223 (92.9) 220 (91.7) 1.0 –
C allele 17 (7.1) 20 (8.3) 0.84 (0.43–1.64) 0.608
Non smokers
TT 80 (86.0) 82 (82.8) 1.0 –
TC 13 (14.0) 17 (17.2) 0.78 (0.35–1.72) 0.543
CC 0 0 – –
Smokers
TT 23 (85.2) 18 (85.7) 1.31 (0.66–2.61) 0.443
TC 4 (14.8) 3 (14.3) 1.37 (0.30–6.30) 0.689
CC 0 0 – –
OR – odds ratio
towards PAHs like benzo(a)pyrene (B[a]P) and 7,12- di-
methyl benz(a)anthracene (7,12-DMBA) and N-nitrosa-
mines, compounds derived from cigarette smoke10. The
same enzyme participates in the metabolic activation of
heterocyclic amines like 2-amino-1-methyl-6-phenylimi-
dazo[4,5-b]pyridine (PhIP), product of cooked meat10. All
this compounds are capable of forming DNA-adducts10.
Furthermore, smoking can affect the level of steroid hor-
mones in a way that lead the increase level of bioavai-
lable testosterone and thus contribute to the develop-
ment and progression of PCa19.
High level of CYP1A1 expression was found in malig-
nant breast tissue, esophageal carcinomas and urinary
bladder tumors10. Studies have shown that CYP1A1*2A
polymorphism is related with different types of tumors.
The polymorphism shows large inter-ethnic variability
in healthy population, with relatively high proportion
among Asians, a bit smaller among African Americans
and smallest in Caucasians8. Only a few studies were
made to asses a potential role of this enzyme in PCa, but
results are inconclusive. Our results showed similar ge-
notype and allele distribution between cases and con-
trols. The frequency of C allele was 0.8 in controls, which
is in agreement with other studies on Caucasians13. The
rare CC homozygote was not found in our population. We
observed no association with PCa risk. Positive associa-
tion of CYP1A1*2A polymorphism with PCa was found
only among Indian8 and Chilean20 population. In study
by Chang at al.21 conducted mostly on Caucasians, the
frequency of C allele was significantly lower in PCa cases
compared to controls suggesting a protective role of mu-
tated allele. Similar results were observed by Silig at al.20
on Turkish population, although lacking statistical sig-
nificance. A frequency of polymorphic genotype in Cro-
atian population was also sligtly higher in controls. Re-
sults imply that ethnicity may affect both, polymorphism
distribution and the PCa risk.
Regarding connection between the polymorphism and
PCa aggressiveness, we obtained lack of association with
all three tested parameters. A polymorphic genotype fre-
quency was even higher in less aggressive PCa. Link be-
tween CYP1A1*2A and PCa with GS ³7 and metastatic
form of cancer was found only in Japanese22. Taking to-
gether these results with those of risk testing, ethnic dif-
ferences can have a significant impact in the cancer etiol-
ogy even possibly in way to cause opposite effects among
ethnicities.
We did not observe any connection between PCa risk
and combined effect of smoking and mutated genotype.
Although smoking affects the occurrence of some can-
cers, epidemiologic studies did not support clear causal
link between smoking and PCa development. PAH-DNA
adducts are increased in prostate tumor cells of ever
smokers Caucasians, but not African Americans23. High-
-risk genotype combinations in Caucasians revealed in-
creased adducts level, which confirms the hypothesis of
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TABLE 3
GENOTYPE AND ALLELE DISTRIBUTION ACCORDING TO THE GLEASON SCORE, TUMOR STAGE AND THE EXISTENCE
OF DISTANT METASTASIS
Variant
N (%) N (%)
OR (95%CI) p
GS<7 GS³7
TT 43 (79.6) 58 (90.6) 1 –
TC 11 (20.4) 6 (9.4) 0.40 (0.14–1.18) 0.097
CC 0 0 – –
T allele 97 (89.8) 122 (95.3) 1 –
C allele 11 (10.2) 6 (4.7) 0.43 (0.15–1.21) 0.434
T<3 T³3
TT 81 (84.4) 20 (90.9) 1 –
TC 15 (15.6) 2 (9.1) 0.54 (0.11–2.56) 0.437
CC 0 0 – –
T allele 177 (92.2) 42 (95.5) 1 –
C allele 15 (7.8) 2 (4.5) 0.56 (0.12–2.55) 0.455
M0 M1
TT 65 (83.3) 36 (90.0) 1 –
TC 13 (16.7) 4 (10.0) 0.56 (0.17–1.83) 0.334
CC 0 0 – –
T allele 143 (91.7) 76 (95.0) 1 –
C allele 13 (8.3) 4 (5.0) 0.58 (0.18–1.84) 0.354
GS – Gleason score, T – tumor stage, M – distant metastasis, OR – odds ratio
PAH activation prior to binding to DNA23. Such results
were not obtained for African Americans, indicating that
association between smoking and PAH-DNA adducts dif-
fers by race and is under the influence of genetic vari-
ants. Besides, PAHs may originate from other sources
than smoking like those from grilled meat or ambient air
pollutions which imply the importance of the environ-
ment and lifestyle as a part of multicausal etiology of
PCa.
This is the first such examination in Croatians, con-
ducted on relatively homogenous group. However, the
study suffers from some limitations related to small
number of participants and lack of information about ex-
posure to other carcinogens than smoking. Additional
problem is the low proportion of mutation in Croatians.
Furthermore, in respect to relatively small number of
smokers, we could not additionally stratify them accord-
ing to the extent of tobacco use, which seems important
in risk assessment. However, taking into consideration
our findings with other published results, we can assume
that the ethnic and geographical background could affect
the genotype distribution and the etiology of the disease
and that gene polymorphism itself is not sufficient in the
development of multifactorial diseases such as PCa. Al-
though the results of our study are negative, they should
be validated with larger sample size in order to obtain
more accurate results.
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ISPITIVANJE POVEZANOSTI POLIMORFIZMA CITOKROMA P450 1A1*2A S RIZIKOM
OD KARCINOMA PROSTATE I AGRESIVNO[]U U HRVATSKOJ POPULACIJI
S A @ E T A K
Citokrom P450 1A1 (CYP1A1) je enzim koji sudjeluje u bioaktivaciji raznih endogenih i egzogenih reaktivnih spo-
jeva koji se mogu vezati na DNA i tako izazvati karcinogenezu. Gen koji kodira taj enzim je eksprimiran u tkivu pros-
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tate i polimorfan. CYP1A1*2A genski polimorfizam je povezan s povi{enom aktivno{}u i/ili inducibilno}u enzima {to
mo`e dovesti do nakupljanja genotoksi~nih spojeva i posljedi~no do karcinogeneze. Ispitali smo povezanost tog poli-
morfizma s rizikom od karcinoma prostate i agresivno{}u. Studija ispitivanja parova sastojala se od 120 pacijenata s
karcinomom prostate (PCa) i 120 kontrola s benignom hiperplazijom prostate (BPH), stanovni{tva Hrvatske. Obzirom
na agresivnost, PCa pacijenti su grupirani prema Gleason zbroju (GS), stadiju tumora (T) i postojanju udaljenih me-
tastaza (M). Polimorfizam je analiziran pomo}u lan~ane reakcije polimeraze (PCR). Nismo uo~ili povezanost izme|u
mutiranog alela i rizika od PCa, niti s bilo kojim ispitivanim parametrom agresivnosti. [tovi{e, frekvencija polimorfnog
genotipa bila je vi{a u skupini BPH (16,6% naspram 14,2%) i u manje agresivnom obliku PCa (20,4% naspram 9,6% za
GS<7; 15,6% naspram 9,1% za T<3; 16,7% naspram 10,0% za M0). Uspore|uju}i na{e rezultate s drugim objavljenim
rezultatima mo`emo pretpostaviti da etni~ka pripadnost mo`e utjecati na distribuciju i tako utjecati na etiologiju PCa,
~ak mo`da i na na~in da izazove suprotan u~inak kod razli~itih etni~kih skupina. Obzirom na mali broj ispitanika,
rezultate bi trebalo potvrditi na ve}em uzorku.
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